EP Patent

EP2107907B1 — Combination of pemirolast and ramatroban for use in the treatment of inflammatory disorders

Assigned to Cardoz AB · Expires 2012-02-01 · 14y expired

What this patent protects

There is provided combination products comprising (a) pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) ramatroban, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in the treatment of atherosc…

USPTO Abstract

There is provided combination products comprising (a) pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) ramatroban, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in the treatment of atherosclerosis and related conditions.

Drugs covered by this patent

Patent Metadata

Patent number: EP2107907B1
Jurisdiction: EP
Classification: —
Expires: 2012-02-01
Drug substance claim: No
Drug product claim: No
Assignee: Cardoz AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.